Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice
- PMID: 20585032
- DOI: 10.4049/jimmunol.0903888
Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice
Abstract
Anti-CD40L immunotherapy in systemic lupus erythematosus patients was associated with thromboembolism of unknown cause. We previously showed that monoclonal anti-CD40L immune complexes (ICs) activated platelets in vitro via the IgG receptor (FcgammaRIIa). In this study, we examined the prothrombotic effects of anti-CD40L ICs in vivo. Because mouse platelets lack FcgammaRIIa, we used FCGR2A transgenic mice. FCGR2A mice were injected i.v. with preformed ICs consisting of either anti-human CD40L mAb (M90) plus human CD40L, or a chimerized anti-mouse CD40L mAb (hMR1) plus mouse CD40L. ICs containing an aglycosylated form of hMR1, which does not bind FcgammaRIIa, were also injected. M90 IC caused shock and thrombocytopenia in FCGR2A but not in wild-type mice. Animals injected with hMR1 IC also experienced these effects, whereas those injected with aglycosylated-hMR1 IC did not, demonstrating that anti-CD40L IC-induced platelet activation in vivo is FcgammaRIIa-dependent. Sequential injections of individual IC components caused similar effects, suggesting that ICs were able to assemble in circulation. Analysis of IC-injected mice revealed pulmonary thrombi consisting of platelet aggregates and fibrin. Mice pretreated with a thrombin inhibitor became moderately thrombocytopenic in response to anti-CD40L ICs and had pulmonary platelet-thrombi devoid of fibrin. In conclusion, we have shown for the first time that anti-CD40L IC-induced thrombosis can be replicated in mice transgenic for FcgammaRIIa. This molecular mechanism may be important for understanding thrombosis associated with CD40L immunotherapy. The FCGR2A mouse model may also be useful for assessing the hemostatic safety of other therapeutic Abs.
Similar articles
-
The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model.J Immunol. 1999 Apr 1;162(7):4311-8. J Immunol. 1999. PMID: 10201963
-
CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes.J Thromb Haemost. 2014 Dec;12(12):2113-9. doi: 10.1111/jth.12748. Epub 2014 Oct 30. J Thromb Haemost. 2014. PMID: 25287077 Free PMC article.
-
Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.Rheumatology (Oxford). 2006 Feb;45(2):150-6. doi: 10.1093/rheumatology/kei118. Epub 2005 Sep 27. Rheumatology (Oxford). 2006. PMID: 16188945
-
Humanized mouse models of FcR clearance in immune platelet disorders.Blood Rev. 2002 Mar;16(1):3-5. doi: 10.1054/blre.2001.0170. Blood Rev. 2002. PMID: 11913983 Review.
-
Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis.J Thromb Haemost. 2015 Jun;13(6):893-908. doi: 10.1111/jth.12905. Epub 2015 Apr 21. J Thromb Haemost. 2015. PMID: 25900780 Review.
Cited by
-
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.MAbs. 2016 Oct;8(7):1319-1335. doi: 10.1080/19420862.2016.1210747. Epub 2016 Aug 17. MAbs. 2016. PMID: 27532598 Free PMC article.
-
Recent Advances in Costimulatory Blockade to Induce Immune Tolerance in Liver Transplantation.Front Immunol. 2021 Feb 24;12:537079. doi: 10.3389/fimmu.2021.537079. eCollection 2021. Front Immunol. 2021. PMID: 33732228 Free PMC article. Review.
-
Update on CD40 and CD154 blockade in transplant models.Immunotherapy. 2015;7(8):899-911. doi: 10.2217/IMT.15.54. Epub 2015 Aug 13. Immunotherapy. 2015. PMID: 26268734 Free PMC article. Review.
-
FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies.Int J Mol Sci. 2022 Oct 25;23(21):12869. doi: 10.3390/ijms232112869. Int J Mol Sci. 2022. PMID: 36361658 Free PMC article. Review.
-
Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps.Front Immunol. 2022 Dec 6;13:1031185. doi: 10.3389/fimmu.2022.1031185. eCollection 2022. Front Immunol. 2022. PMID: 36561750 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases